Susan served as President and CEO of CURE (now BioCT) from 2013 through October 2017. BioCT provides education and entrepreneurial resources and advocates on behalf of the bioscience industry in Connecticut.
Today, Susan is Vice President of CURE Collaborations, LLC, a leader of the CURE Commons accelerator programs, and an Entrepreneur in Residence at Yale’s Office of Cooperative Research. She is also a board member of Carogen, LambdaVision, Bioxiness, Thames River Innovation Partners.
Earlier in her career, Susan was a Co-Founder and CEO of Rib-X Pharmaceuticals (now Melinta). During her 11-year tenure she led the company through $160 million of investment and development of novel antibiotic treatments.
Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B.A. from Connecticut College. Earlier in her career she served as a Research Scientist and Licensing Executive at Pfizer.
Find out more about Startup Grind